307 related articles for article (PubMed ID: 30333428)
21. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
22. Lenvatinib-Induced Tumor-Related Hemorrhages in Patients with Large Hepatocellular Carcinomas.
Uchida-Kobayashi S; Kageyama K; Yamamoto A; Ikenaga H; Yoshida K; Kotani K; Kimura K; Odagiri N; Hagihara A; Fujii H; Enomoto M; Tamori A; Kubo S; Miki Y; Kawada N
Oncology; 2021; 99(3):186-191. PubMed ID: 33032274
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(10):641-651. PubMed ID: 34515171
[TBL] [Abstract][Full Text] [Related]
25. [Lenvatinib:new molecular targeted therapy of hepatocellular carcinoma -the progress and future perspective].
Kobayashi M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(1):36-44. PubMed ID: 30626852
[No Abstract] [Full Text] [Related]
26. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma.
Osawa Y; Gozawa R; Koyama K; Nakayama T; Sagoh T; Sunaga H
Intern Med; 2018 Apr; 57(7):1015-1019. PubMed ID: 29225265
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
29. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis.
Kawanishi Y; Kuwahara M; Utsunomiya M; Ishida N; Ishikawa Y; Hiroi M; Akimori T
Clin J Gastroenterol; 2021 Feb; 14(1):288-292. PubMed ID: 33108567
[TBL] [Abstract][Full Text] [Related]
30. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib.
Kodama K; Kawaoka T; Namba M; Uchikawa S; Ohya K; Morio K; Nakahara T; Murakami E; Yamauchi M; Hiramatsu A; Imamura M; Chayama K; Aikata H
Oncology; 2019; 97(2):75-81. PubMed ID: 31242488
[TBL] [Abstract][Full Text] [Related]
31. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer.
Cabanillas ME; Takahashi S
Semin Oncol; 2019 Feb; 46(1):57-64. PubMed ID: 30685073
[TBL] [Abstract][Full Text] [Related]
32. Liver Function and Bleeding Complications Associated with Lenvatinib.
Ishihara K
J Gastrointestin Liver Dis; 2021 May; 30(2):185-187. PubMed ID: 33951114
[No Abstract] [Full Text] [Related]
33. Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L; Tovoli F; Piscaglia F
Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
[TBL] [Abstract][Full Text] [Related]
34. Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma.
Kuorda H; Abe T; Fujiwara Y; Okamoto T; Yonezawa M; Sato H; Endo K; Oikawa T; Sawara K; Takikawa Y
World J Gastroenterol; 2019 May; 25(19):2365-2372. PubMed ID: 31148907
[TBL] [Abstract][Full Text] [Related]
35. Early Relative Change in Hepatic Function with Lenvatinib for Unresectable Hepatocellular Carcinoma.
Hiraoka A; Kumada T; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Imai M; Joko K; Koizumi Y; Hiasa Y; Michitaka K;
Oncology; 2019; 97(6):334-340. PubMed ID: 31466068
[TBL] [Abstract][Full Text] [Related]
36. Lenvatinib-induced Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma.
Imakura T; Sato S; Tomonari T; Murakami K; Takahashi N; Naito N; Mima M; Kagawa K; Koyama K; Nishimura H; Kawano H; Nokihara H; Azuma M; Takayama T; Nishioka Y
Intern Med; 2022 Apr; 61(8):1211-1217. PubMed ID: 34544944
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yanagimoto H; Toyama H; Kodama Y; Fukumoto T
Anticancer Res; 2021 Sep; 41(9):4555-4562. PubMed ID: 34475083
[TBL] [Abstract][Full Text] [Related]
38. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
39. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib-induced destructive thyroiditis.
Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
